Sanjay Singh

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies
    Kailash C Pandey
    Malaria Research Group, International Centre for Genetic Engineering and Biotechnology, P O Box 10504, Aruna Asaf Ali Marg, New Delhi 110067, India
    Mol Biochem Parasitol 123:23-33. 2002
  2. pmc Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1
    Sanjay Singh
    Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20852, USA
    Infect Immun 71:6766-74. 2003
  3. ncbi request reprint Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations
    Aaron P Miles
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Twinbrook I Room 1118, Rockville, MD 20852, USA
    Vaccine 23:2530-9. 2005
  4. pmc Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity
    Sanjay Singh
    Antigen Research Section, Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases National Institutes of Health, TW1, Rockville, Maryland 20852, USA
    Infect Immun 74:4573-80. 2006
  5. pmc Recombinant Plasmodium falciparum reticulocyte homology protein 4 binds to erythrocytes and blocks invasion
    Deepak Gaur
    Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook III, 12735 Twinbrook Parkway, Bethesda, MD 20892 8132, USA
    Proc Natl Acad Sci U S A 104:17789-94. 2007
  6. pmc posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate
    Birgitte Giersing
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, Twinbrook I, Room 1210A, 5640 Fisher Lane, Rockville, Maryland 20852, USA
    Infect Immun 73:3963-70. 2005
  7. pmc Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice
    Kathrin Kastenmüller
    Vaccine Research Center and Cellular Immunology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Infect Immun 81:789-800. 2013
  8. pmc The cysteine-rich interdomain region from the highly variable plasmodium falciparum erythrocyte membrane protein-1 exhibits a conserved structure
    Michael M Klein
    Structural Biology Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America
    PLoS Pathog 4:e1000147. 2008
  9. pmc Domain III of Plasmodium falciparum apical membrane antigen 1 binds to the erythrocyte membrane protein Kx
    Kentaro Kato
    Laboratory of Malaria and Vector Research and Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8132, USA
    Proc Natl Acad Sci U S A 102:5552-7. 2005
  10. ncbi request reprint Antibody responses to Plasmodium falciparum vaccine candidate antigens in three areas distinct with respect to altitude
    Godfree Mlambo
    Malaria Research Institute, Department of Molecular Microbiology and Immunology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Acta Trop 100:70-8. 2006

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies
    Kailash C Pandey
    Malaria Research Group, International Centre for Genetic Engineering and Biotechnology, P O Box 10504, Aruna Asaf Ali Marg, New Delhi 110067, India
    Mol Biochem Parasitol 123:23-33. 2002
    ..falciparum field isolate that invades erythrocytes using multiple pathways. These observations support the development of recombinant PfF2 as a vaccine candidate for P. falciparum malaria...
  2. pmc Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1
    Sanjay Singh
    Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20852, USA
    Infect Immun 71:6766-74. 2003
    ..falciparum. The protection correlated with antibody-dependent mechanisms. Thus, this new construct, E. coli MSP1(42), is a viable candidate for human vaccine trials...
  3. ncbi request reprint Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations
    Aaron P Miles
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Twinbrook I Room 1118, Rockville, MD 20852, USA
    Vaccine 23:2530-9. 2005
    ....
  4. pmc Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity
    Sanjay Singh
    Antigen Research Section, Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases National Institutes of Health, TW1, Rockville, Maryland 20852, USA
    Infect Immun 74:4573-80. 2006
    ....
  5. pmc Recombinant Plasmodium falciparum reticulocyte homology protein 4 binds to erythrocytes and blocks invasion
    Deepak Gaur
    Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook III, 12735 Twinbrook Parkway, Bethesda, MD 20892 8132, USA
    Proc Natl Acad Sci U S A 104:17789-94. 2007
    ..These findings suggest that, although PfRH4 is required for invasion of neuraminidase-treated erythrocytes by Dd2/NM, it is inaccessible for antibody-mediated inhibition of the invasion process...
  6. pmc posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate
    Birgitte Giersing
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, Twinbrook I, Room 1210A, 5640 Fisher Lane, Rockville, Maryland 20852, USA
    Infect Immun 73:3963-70. 2005
    ..coli- and P. pastoris-derived antigens are immunologically and functionally equivalent and are unaffected by the posttranslational modification resulting from expression in these two systems...
  7. pmc Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice
    Kathrin Kastenmüller
    Vaccine Research Center and Cellular Immunology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Infect Immun 81:789-800. 2013
    ..Overall, these data suggest that full-length CS proteins and poly(I · C)LC or GLA-SE offer a simple vaccine formulation to be used alone or in combination with other vaccines for preventing malaria infection...
  8. pmc The cysteine-rich interdomain region from the highly variable plasmodium falciparum erythrocyte membrane protein-1 exhibits a conserved structure
    Michael M Klein
    Structural Biology Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America
    PLoS Pathog 4:e1000147. 2008
    ..This new understanding of PfEMP1 structure will allow the use of better-defined PfEMP1 domains for functional studies, for the design of candidate vaccines, and for understanding the molecular basis of cytoadherence...
  9. pmc Domain III of Plasmodium falciparum apical membrane antigen 1 binds to the erythrocyte membrane protein Kx
    Kentaro Kato
    Laboratory of Malaria and Vector Research and Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8132, USA
    Proc Natl Acad Sci U S A 102:5552-7. 2005
    ....
  10. ncbi request reprint Antibody responses to Plasmodium falciparum vaccine candidate antigens in three areas distinct with respect to altitude
    Godfree Mlambo
    Malaria Research Institute, Department of Molecular Microbiology and Immunology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Acta Trop 100:70-8. 2006
    ..falciparum in vitro. Our data revealed that highest growth inhibition correlated with the highest levels of MSP-1 antibody values...
  11. ncbi request reprint The real greenhouse effect
    Sanjay Singh
    Indian J Dermatol Venereol Leprol 73:52; author reply 52. 2007
  12. pmc Floating osmotic drug delivery system of ranitidine hydrochloride: development and evaluation--a technical note
    Pramod Kumar
    Department of Pharmaceutics, Institute of Technology, Banaras Hindu University, Varanasi 221005, U P, India
    AAPS PharmSciTech 9:480-5. 2008
  13. doi request reprint Studies on biodegradable polymeric nanoparticles of risperidone: in vitro and in vivo evaluation
    Madaswamy S Muthu
    Institute of Medical Sciences, Department of Pharmacology, Banaras Hindu University, Varanasi 221005, India
    Nanomedicine (Lond) 3:305-19. 2008
    ..The aim of this work was to develop extended-release risperidone nanoparticles for parenteral delivery (intravenous) and to reduce the dose-dependent extrapyramidal side effects of risperidone...